Literature DB >> 23958880

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.

David Monderer1, Alexandrine Luseau, Amélie Bellec, Emmanuelle David, Stéphanie Ponsolle, Soraya Saiagh, Sylvain Bercegeay, Philippe Piloquet, Marc G Denis, Laurence Lodé, Françoise Rédini, Marine Biger, Dominique Heymann, Marie-Françoise Heymann, Ronan Le Bot, François Gouin, Frédéric Blanchard.   

Abstract

Chondrosarcomas are cartilage-forming, poorly vascularized tumors. They represent the second malignant primary bone tumor of adults after osteosarcoma, but in contrast to osteosarcoma they are resistant to chemotherapy and radiotherapy, surgical excision remaining the only therapeutic option. Few cell lines and animal models are available, and the mechanisms behind their chemoresistance remain largely unknown. Our goal was to establish new cell lines and animal cancer models from human chondrosarcoma biopsies to study their chemoresistance. Between 2007 and 2012, 10 chondrosarcoma biopsies were collected and used for cell culture and transplantation into nude mice. Only one transplanted biopsy and one injected cell line has engrafted successfully leading to conventional central high-grade chondrosarcoma similar to the original biopsies. In culture, two new stable cell lines were obtained, one from a dedifferentiated and one from a grade III conventional central chondrosarcoma biopsy. Their genetic characterization revealed triploid karyotypes, mutations in IDH1, IDH2, and TP53, deletion in CDKN2A and/or MDM2 amplification. These cell lines expressed mesenchymal membrane markers (CD44, 73, 90, 105) and were able to produce a hyaline cartilaginous matrix when cultured in chondrogenic three-dimensional (3D) pellets. Using a high-throughput quantitative RT-PCR approach, we observed that cell lines cultured in monolayer had lost expression of several genes implicated in cartilage development (COL2A1, COMP, ACAN) but restored their expression in 3D cultures. Chondrosarcoma cells in monolayer were sensitive to several conventional chemotherapeutic agents but became resistant to low doses of mafosfamide or doxorubicin when cultured in 3D pellets, in parallel with an altered nucleic accumulation of the drug. Our results indicate that the cartilaginous matrix produced by chondrosarcoma cells may impair diffusion of several drugs and thus contribute to chemoresistance. Therefore, 3D chondrogenic cell pellets constitute a more relevant model to study chondrosarcoma chemoresistance and may be a valuable alternative to animal experimentations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23958880     DOI: 10.1038/labinvest.2013.101

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  16 in total

1.  Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1.

Authors:  Rieko Oyama; Fusako Kito; Mami Takahashi; Marimu Sakumoto; Kumiko Shiozawa; Zhiwei Qiao; Rei Noguchi; Takashi Kubo; Shunichi Toki; Fumihiko Nakatani; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2019-02-08       Impact factor: 4.174

2.  An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.

Authors:  Jolieke G van Oosterwijk; Jacqueline R M Plass; Danielle Meijer; Ivo Que; Marcel Karperien; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2014-10-21       Impact factor: 4.064

3.  Centrosome amplification in chondrosarcomas: A primary cell culture and cryopreserved tumor sample study.

Authors:  Carla Aparecida Pinheiro; Iberê Cauduro Soares; Valter Penna; Jeremy Squire; Rui Manuel Vieira Reis; Sandra Regina Morini da Silva; Isabela de Carvalho; Marjori Leiva Camparoto; Maicon Fernando Zanon da Silva; Adhemar Longatto Longatto Filho
Journal:  Oncol Lett       Date:  2017-01-23       Impact factor: 2.967

4.  Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma.

Authors:  Megan E Roche; Zhao Lin; Diana Whitaker-Menezes; Tingting Zhan; Karoly Szuhai; Judith V M G Bovee; John A Abraham; Wei Jiang; Ubaldo Martinez-Outschoorn; Atrayee Basu-Mallick
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-10       Impact factor: 5.187

5.  Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.

Authors:  L Sun; Y Li; Z Jiang; J Zhang; H Li; B Li; Z Ye
Journal:  Tumour Biol       Date:  2015-12-16

Review 6.  In vitro three-dimensional cell cultures for bone sarcomas.

Authors:  Javier Munoz-Garcia; Camille Jubelin; Aurélie Loussouarn; Matisse Goumard; Laurent Griscom; Axelle Renodon-Cornière; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2021-07-06       Impact factor: 4.072

7.  Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.

Authors:  Aurélien Voissiere; Elodie Jouberton; Elise Maubert; Françoise Degoul; Caroline Peyrode; Jean-Michel Chezal; Élisabeth Miot-Noirault
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

8.  Do Patient-derived Spheroid Culture Models Have Relevance in Chondrosarcoma Research?

Authors:  Ruichen Ma; Jonathan Mandell; Feiqi Lu; Tanya Heim; Karen Schoedel; Anette Duensing; Rebecca J Watters; Kurt R Weiss
Journal:  Clin Orthop Relat Res       Date:  2021-03-01       Impact factor: 4.755

9.  In vitro engineering of human 3D chondrosarcoma: a preclinical model relevant for investigations of radiation quality impact.

Authors:  Dounia Houria Hamdi; Sofia Barbieri; François Chevalier; Jean-Emmanuel Groetz; Florence Legendre; Magali Demoor; Philippe Galera; Jean-Louis Lefaix; Yannick Saintigny
Journal:  BMC Cancer       Date:  2015-08-08       Impact factor: 4.430

10.  Identification of an easy to use 3D culture model to investigate invasion and anticancer drug response in chondrosarcomas.

Authors:  Eva Lhuissier; Céline Bazille; Juliette Aury-Landas; Nicolas Girard; Julien Pontin; Martine Boittin; Karim Boumediene; Catherine Baugé
Journal:  BMC Cancer       Date:  2017-07-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.